Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
LUPRON INJECTION |
| Manufacturer |
|
TAP Pharmaceutical Products, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
GnRH analogue. |
| Generic Name |
|
Leuprolide acetate 5mg/mL; SC inj; contains benzyl alcohol. |
| Also |
• LUPRON DEPOT-3 MONTH 22.5mg
• LUPRON DEPOT-4 MONTH 30mg
• LUPRON DEPOT 7.5mg
|
| Indications |
|
Palliative treatment of advanced prostatic carcinoma. |
| Children |
|
Not applicable. |
| Adults |
|
1mg SC daily. Rotate inj site. |
| Precautions |
|
May use SC form for first 2 weeks of treatment for patients at risk of worsening symptoms of metastatic vertebral lesions and/or urinary obstruction to facilitate treatment withdrawal. Metastatic vertebral lesions. Urinary obstruction. Monitor serum testosterone, PSA, acid phosphatase. Instruct patient on correct self administration. |
| Adverse Reactions |
|
Hot flashes, initial worsening of signs/symptoms (eg, bone pain, urinary tract obstruction, hematuria), edema, GI upset, pain, cardiovascular events, CNS and antiandrogenic effects, asthenia, spinal cord compression; anaphylactoid, photosensitivity, local reactions. |
| How Supplied |
Depot single-dose syringe—1 (w. diluent)
Inj multidose vial (2.8mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
